RXDX Prometheus Biosciences, Inc.

Ignyta, Inc., a precision oncology biotechnology company, engages in discovering, in-licensing or acquiring, developing, and commercializing molecularly targeted therapies for eradicating residual diseases. Its products pipeline includes entrectinib, a tyrosine kinase inhibitor directed to the tropomyosin receptor kinase family tyrosine kinase receptors, ROS1, and anaplastic lymphoma kinase proteins, which is in Phase II and two Phase I clinical studies in molecularly defined adult patient populations for the treatment of solid tumors, as well as in Phase I/Ib clinical study in pediatric patients with advanced solid tumor malignancies; RXDX-105, an orally bioavailable and vascular endothelial growth factor receptor, and small molecule tyrosine kinase inhibitor of RET-driven solid tumors; and RXDX-106, a pseudo-irreversible inhibitor, which is in late preclinical development. The company was founded in 2011 and is headquartered in San Diego, California.

$58.95  +1.41 (2.45%)
As of 09/30/2022 15:59:59 EST     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Mid cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  02/18/2014
Outstanding shares:  40,904,098
Average volume:  745,543
Market cap:   $2,353,621,799
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Sedol:      BMZ9Z11
Valuation   (See tab for details)
PE ratio:   -22.28
PB ratio:   11.16
PS ratio:   474.90
Return on equity:   -52.40%
Net income %:   -2,185.55%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy